Table 3.
Benign | Malignant | Non-neoplastic | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Entity | ≤5 cm | ≤3 cm | ≤2 cm | Entity | ≤5 cm | ≤3 cm | ≤2 cm | Entity | ≤5 cm | < 3 cm | ≤2 cm |
Overall | 465 (66.43%) | 273 (73.39%) | 124 (71.26%) | 155 (22.14%) | 57 (15.32%) | 24 (13.79%) | 80 (11.43%) | 42 (11.29%) | 26 (14.94%) | ||
Fibroma | 28 (4.0%) | 23 (6.18%) | 13 (7.47%) | Alveolar soft part sarcoma | 4 (0.57%) | – | – | Bursitis | 6 (0.86%) | 4 (1.08%) | 3 (1.72%) |
Fibromatosis | 29 (4.14%) | 17 (4.57%) | 7 (4.02%) | Angiosarcoma of soft tissue | 5 (0.71%) | 2 (0.54%) | – | Ganglion | 45 (6.43%) | 26 (6.99%) | 15 (8.62%) |
Glomus tumors | 1 (0.14%) | – | – | Chondrosarcoma | 2 (0.29%) | 1 (0.27%) | – | Haematoma | 3 (0.43%) | – | – |
Haemangioma | 63 (9.0%) | 39 (10.48%) | 14 (8.05%) | Clear cell sarcoma of soft tissue | 3 (0.43%) | 1 (0.27%) | 1 (0.57%) | Lipoma arborescens | 2 (0.29%) | – | – |
Lipoma | 47 (6.71%) | 12 (3.23%) | 2 (1.15%) | Dermatofibrosarcoma protuberans | 1 (0.14%) | 1 (0.27%) | – | Pseudotumor | 7 (1.0%) | 4 (1.08%) | 2 (1.15%) |
Lymphangioma | 1 (0.14%) | – | – | Epithelioid sarcoma | 4 (0.57%) | 3 (0.81%) | 1 (0.57%) | Others | 17 (2.43%) | 8 (2.15%) | 6 (3.45%) |
Myopericytoma | 3 (0.43%) | 2 (0.54%) | 2 (1.15%) | Ewing-Sarcoma | 1 (0.14%) | – | – | ||||
Myositis ossificans | 2 (0.29%) | 2 (0.54%) | – | Extraskeletal osteosarcoma | 1 (0.14%) | – | – | ||||
Myxoma | 20 (2.86%) | 7 (1.88%) | 3 (1.72%) | Extrapleural solitary fibrous tumour | 5 (0.71%) | – | – | ||||
Nodular fasciitis | 24 (3.43%) | 18 (4.84%) | 12 (6.9%) | Fibrosarcoma | 3 (0.43%) | 3 (0.81%) | 1 (0.57%) | ||||
Perineurioma | 1 (0.14%) | – | – | Leyomyosarcoma | 14 (2.0%) | 9 (2.42%) | 5 (2.87%) | ||||
Schwannoma | 83 (11.86%) | 54 (14.52%) | 22 (12.64%) | Liposarcoma a | 23 (3.29%) | 4 (1.08%) | 3 (1.72%) | ||||
Tenosynovial giant cell tumor | 163 (23.29%) | 99 (26.61%) | 49 (28.16%) | Lymphoma | 7 (1.0%) | 1 (0.27%) | – | ||||
Metastasis | 3 (0.43%) | 1 (0.27%) | – | ||||||||
Malignant peripheral nerve sheath tumor | 1 (0.14%) | – | – | ||||||||
Myofibroblastic tumor | 5 (0.71%) | 4 (1.08%) | 1 (0.57%) | ||||||||
Myxofibrosarcoma | 19 (2.71%) | 6 (1.61%) | 4 (2.3%) | ||||||||
Rhabdomyosarcoma | 4 (0.57%) | 1 (0.27%) | – | ||||||||
Synovial sarcoma | 20 (2.86%) | 9 (2.42%) | 3 (1.72%) | ||||||||
Undifferentiated pleomorphic sarcoma | 25 (3.57%) | 8 (2.15%) | 4 (2.3%) | ||||||||
Sarcoma, not other specified | 5 (4.29%) | 3 (0.81%) | 1 (0.57%) |
aof those classified as low-grade liposarcoma/aypical lipomatous tumor: 12 ≤ 5 cm (1.71%), 2 ≤ 3 cm (0.54%), 2 ≤ 2 cm (1.15%)